Seres Therapeutics appoints Dr Lisa von Moltke as new Chief Medical Officer

pharmafile | April 9, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Dr Lisa von Moltke has left Aklermes and has joined Seres Therapeutics as its new Chief Medical Officer.

Chief Executive Officer at Seres, Eric Shaff, said Seres will benefit from von Moltke’s “extensive experience directing successful development programs, leading clinical teams, and interacting with regulatory agencies across multiple areas of medicine.”

Lisa von Moltke said she is excited about joining the company adding: “I look forward to working with the team to bring Seres’ innovative microbiome therapeutic approach, a new modality of medicine, forward to patients with serious diseases.”

Dr von Moltke moves to Seres after a five year stint as the Senior Vice President and Head of Clinical Development at Alkermes. Before that, she held positions as Vice President of Clinical and Exploratory Pharmacology at Sanofi Genzyme and Senior Director of Translational Medicine at Millennium Pharmaceuticals/Takeda Oncology.

She also served as president of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology.

She earned her BA degree from Wellesley College and her M.D. from the Michigan State University College of Human Medicine. She went on to train in internal medicine at the New England Medical Center Hospital.

Related Content

No items found

Latest content